Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7856.018 | 1.0659 | 1.1408 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7856.018 | 0.9831 | 0.9639 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7856.018 | 1.0216 | 1.0459 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7856.018 | 1.0102 | 1.0218 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7856.018 | 0.9954 | 0.9901 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7856.018 | 0.9327 | 0.8570 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7856.018 | 1.0040 | 1.0086 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7856.018 | 0.9441 | 0.8811 | 0.9388 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7857.042 | 1.0014 | 1.0024 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7857.042 | 0.9622 | 0.9364 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7857.042 | 0.9815 | 0.9689 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7857.042 | 1.0028 | 1.0047 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7857.042 | 0.9714 | 0.9519 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7857.042 | 0.8589 | 0.7602 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7857.042 | 0.8930 | 0.8188 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7857.042 | 0.9132 | 0.8531 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7857.042 | 0.8504 | 0.7456 | 1.1910 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7860.042 | 1.0026 | 1.0078 | 0.6736 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7860.042 | 1.0594 | 1.1789 | 0.6736 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7860.042 | 1.0164 | 1.0489 | 0.6736 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7860.042 | 1.0412 | 1.1235 | 0.6736 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7860.042 | 1.0453 | 1.1358 | 0.6736 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7860.042 | 1.0012 | 1.0035 | 0.6736 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7860.042 | 0.9688 | 0.9079 | 0.6736 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7860.042 | 0.9719 | 0.9172 | 0.6736 |